As a notable example, combination therapy involving the administration of direct activation of PP2A by SMAPS with the addition of other therapeutic agents have shown great promise in preclinical studies of COPD and LC [82, 158, 188]. This evidence concerns the gene PTPA and chronic obstructive pulmonary disease.